PFIZER INCORPORATED

Working for a healthier world

6-Mar-13

PFIZER INCORPORATED
PRESENTED BY : SEM II 2012-2014
Afzal housaain PH 1202 Akhil Vyas - PH 1203 Akshay A Nahar PH 1204 Anudeep - PH 1208 Arvind Maurya - PH 1209 Ashok Kondhare - PH 1210
2 6-Mar-13

Welcome to Pfizer
We are the worlds leading healthcare company with:

A 155-year history originating in Brooklyn, NY A market capitalization ranked 4th worldwide Over $45 billion in annual sales in over 150 countries 122,000 colleagues worldwide The largest R&D budget in the world at nearly $8 billion

6-Mar-13 3

VISION
We will be recognized for meeting the diverse medical needs of patients in Emerging Markets around the world in an innovative, socially responsible and commercially viable manner.
Pfizer world headquarters in New York , USA
4 6-Mar-13

HISTORY
Pfizer, Inc. is an American multinational pharmaceutical corporation headquartered in New York City , and with its research headquarters in Groton , Connecticut, United States. It is the world's largest pharmaceutical company by revenues. ($ 67.4 billion) (2011) (top position) Pfizer is named after German-American cousins Charles Pfizer and Charles Erhart (originally from Ludwigsburg, Germany) who launched a fine chemicals business, Charles Pfizer and Company, from a building at the Williamsburg, Brooklyn in 1849.

6-Mar-13

HISTORY
There, they produced an antiparasitic called santonin. This was an immediate success, although it was the production of citric acid that really kick-started Pfizer's growth in the 1880. World War I caused a shortage of calcium citrate that Pfizer imported from Italy for the manufacture of citric acid, and the company began a search for an alternative supply. Pfizer chemists learned of a fungus that ferments sugar to citric acid and were able to commercialize production of citric acid from this source in 1919. These skills were applied to the mass production of penicillin during World War II.

6-Mar-13

HISTORY
By the 1950s, Pfizer was established in (Belgium, Brazil, Canada, Cuba, Iran, Mexico, Panama, Puerto Rico, Turkey and the United Kingdom.)

During the 1980s and 1990s Pfizer underwent a period of growth sustained by the discovery and marketing of multiple successful drugs (Zoloft, Lipitor, Norvasc, Zithromax, Aricept,Diflucan, Viagra).

6-Mar-13

ACQUISITIONS
COMPANY NAME YEAR OF ACQUISITION

WARNERLAMBERT PHARMACIA

2000 2002 2009 2010

8 6-Mar-13

WYETH KING PHARMACEUTICALS

PFE Market Cap: Employees: 190.47B 98,800 -0.16 62.22B

MRK 127.41B 86,000 -0.04 47.82B

NVS 154.93B 123,686 -0.07 57.49B

SNY 126.58B 113,719 0.01 46.89B

Industry 1.37B 1.67K 0.08 2.28B

Qtrly Rev Growth (yoy):

Revenue (ttm): Gross Margin (ttm): EBITDA (ttm): Operating Margin (ttm): Net Income (ttm): EPS (ttm): P/E (ttm): PEG (5 yr expected): P/S (ttm):

0.80
26.77B 0.31 9.75B 1.28 20.26 5.63 3.06

0.66
17.78B 0.23 6.77B 2.20 19.05 3.55 2.69
9

0.68
16.42B 0.21 8.64B 3.55 18.06 4.07 2.68

0.71
18.69B 0.25 7.76B 2.93 16.42 2.56 2.68 2.11

0.54
130.49M 0.12 N/A 0.56 17.03 0.73
6-Mar-13

10

6-Mar-13

M &A
Mergers and acquisitions (abbreviated M&A) is an aspect of corporate strategy, corporate finance and management dealing with the buying, selling, dividing and combining of different companies and similar entities that can help an enterprise grow rapidly in its sector or location of origin, or a new field or new location, without creating a subsidiary, other child entity or using a joint venture.

11

6-Mar-13

SEGMENTS
Pfizer Limited operates in three segments: 1. Pharmaceuticals, 2. Animal Health and 3. Services.
The Pharmaceuticals business consists of manufacturing of drugs and formulations, trading of formulations, and also includes rendering of marketing services.
12 6-Mar-13

SEGMENTS
The Animal Health business has a presence primarily in the animal health and poultry market segments and also includes rendering of marketing services. Services segment consist of clinical development operations primarily include conducting clinical trials, product development and undertaking data management for drug development.

13

6-Mar-13

DIVISIONS
Pfizer has four divisions: Human Health ($44.28B in 2005 sales), Consumer Healthcare ($3.87B in 2005 sales), Animal Health ($2.2B in 2005 sales), and Corporate Groups (which includes legal, finance, and HR. On June 26, 2006, Pfizer announced that it would sell its Consumer Healthcare unit. (manufacturer of Listerine, Nicorette, Visine, Sudafed and Neosporin) to Johnson & Johnson for $16.6 billion.
14 6-Mar-13

SEGMENTS

15

6-Mar-13

Central Nervous System

Ophthalmology

Cardiovascular

Respiratory Infectious Disease/HIV

Diabetes Endocrinology

Oncology Pain/Inflammation Urogenital/Gyn.

16

6-Mar-13 16

Global R &D of PFIZER

Pfizer Global Research and Development is Pfizer's research and development division. In 2007, Pfizer invested $8.1 billion in research and development, the largest R&D investment in the pharmaceutical industry. Pfizer's human research and development operations are headquartered in New London, CT, and its animal health research and development operations are headquartered in Kalamazoo, Michigan.

17

6-Mar-13

18

6-Mar-13

PURSUING INNOVATION
The pursuit of innovation is basic to Pfizer's culture. Pfizer scientists have produced innovative breakthroughs in a wide range of research areas, including depression, erectile dysfunction, high cholesterol, HIV infection, hypertension, bacterial infections and systemic fungal infections. And today pfizer taking on some of the world's most difficult diseases, including cancer, arthritis, and osteoporosis.
19 6-Mar-13

CORPORATE MANAGEMENT

Mr. Jeffrey B. Kindler

Mr. David Shedlarz

Mr. Ian C. Read

Dr. Martin Mackay

Dr. Freda C. Lewis-Hall M.D., FAPA

20

6-Mar-13

BOARD OF DIRECTORS
Mr. R.A. Shah Chairman. Mr. R.A. Shah was first appointed on the Board on November 9, 1965. Mr. Kewal Handa - Managing Director (Upto August 15, 2012) Mr. K. Handa was appointed to the Board on December 16, 1996. Mr. Pradip P. Shah Director Mr. Pradip P. Shah was appointed to the Board on December 7, 1999. Mr. Aijaz Tobaccowalla Managing Director (from August 16, 2012)
21 6-Mar-13

PFIZER IN INDIA
Pfizer Limited (India) has a turnover of US$ 184.96 million (March 2012). One of the highest spenders in pharmaceutical R&D globally, Pfizer has made clinical research investments of US$ 1.18 million (March 2012) in India . The company was awarded the FICCI SEDF (Socio Economic Development Foundation) Certificate of Commendation for its social responsibility efforts. Pfizer has won several awards including that for the multinational pharmaceutical company of the year and the most respected MNC .
22

6-Mar-13

ABOUT PRODUCTS
Six Pfizer brands feature among the Top 100 pharmaceutical brands in India . Two of Pfizer India's brands -- Corex (Cough Formulation) and Becosules (Multivitamin) -- continue to rank among the Top 15 pharmaceutical drug brands. Pfizer has won the Golden Peacock Innovative Product for Magnex (Sulperazon). Becosules has won the Most Trusted Brand Award.
23 6-Mar-13

PRODUCTS
The following is a list of key prescription pharmaceutical products. The names shown are all registered trademarks of Pfizer. Pfizer had the greatest number of blockbuster products in 2009 with 14, which includes five inherited Inc. Chap Stick Xanax (alprazolam) 2 mg tri-score tablets Bottles of the antidepressant Zoloft
24 6-Mar-13

25

6-Mar-13

HUMAN HEALTH
Accupril (quinapril) for hypertension treatment. Advil (ibuprofen) Alesse (levonorgestrel/ethinyl estradiol) an oral contraceptive. Aricept (donepezil) for Alzheimer's disease Bextra (Valdecoxib) for arthritis. Caduet (amlodipine) and (atorvastatin) for cholesterol and hypertension. Diflucan (fluconazole) for antifungal drug Eryc (erythromycin) an antibiotic Viagra (sildenafil) for erectile dysfunction
26 6-Mar-13

Viagra
Treats erectile dysfunction (ED) Cannot exceed the maximum dose of 25mg in 48 hours

Benadryl
Treats allergy symptoms Treating adult allergic reaction 25-50 mg every 4-6 hours

Cefazolin
To reduce the development of drug- resistant bacteria Moderate to sever infection 500 mg- 1 gram every 6-8 hours
27 6-Mar-13

PMED TECHNOLOGY
Powder Med developed the Particle Mediated Epidermal Delivery (PMED) technology. PMED delivers DNA vaccines into the skin without needles in a dry powder formulation of gold particles. The particles are accelerated by helium gas in a hand-held device and propelled into the skin. This needlefree delivery is ideal for the delivery of DNA vaccines. PowderMed was acquired by Pfizer in 2006 and the PMED technology is being used in Pfizer vaccine programs.

28

6-Mar-13

29

6-Mar-13

30

6-Mar-13

31

6-Mar-13

MOST VALUED BY OUR PEERS AND INDUSTRY

One of the Top 50 Companies in America
One of the Worlds Best Companies for Leaders One of the Top 50 Diversity Employers

100 Best Companies to Work For in America Americas Most Admired Pharmaceutical Company #2 in Training and Developing Employees

One of top 25 employers for MBAs

32

6-Mar-13 32

CONTOVERSIAL
Brigham Young University (Celebrex Royalty) Lawsuit over GMO virus Blue Cross Blue Shield lawsuit Off label promotional practices of GABAPENTIN

33

6-Mar-13

CONTROVERSIAL
Off label promotional practices
In 1993, the U.S. Food and Drug Administration (FDA) approved gabapentin (Neurontin, Pfizer) only for treatment of seizures. WarnerLambert, used activities continuing medical education and research, sponsored articles about the drug for the medical literature, and alleged suppression of unfavourable study results, to promote gabapentin. WarnerLambert admitted to charges that it violated FDA regulations by promoting the drug for pain, psychiatric conditions, migraine, and other unapproved uses, and paid $430 million to resolve criminal and civil health care liability charges

Blue Cross Blue Shield lawsuit

Health insurance company Blue Cross Blue Shield (BCBS) filed a lawsuit against Pfizer for reportedly illegally marketing their drugs Bextra, Geodon and Lyrica. BCBS is reporting that Pfizer used "kickbacks" and wrongly persuaded doctors to prescribe the drugs. Fierce Pharma reported that "According to the suit, the drugmaker not only handed out those "misleading" materials on off-label uses, but sent doctors on Caribbean junkets and paid them $2,000 honoraria in return for their 6-Mar-13 listening to lectures about Bextra.

34

SWOT ANALYSIS
STRENGTH : Strong sales and marketing infrastructure. Strong R & D department. R &D innovation in broad therapeutic coverage. Marketing strength in major geographical & therapeutic areas.
35 6-Mar-13

SWOT ANALYSIS
WEAKNESS : Very limited penetration in biologics market. Discontinuation of products in latter stage of development. OPPORTUNITIES : Biological market expansion. Strengths, providing pfizer with strong product therefore revenue growth.
36 6-Mar-13

SWOT ANALYSIS

THREATS : Considerable exposure to generic competition, focal point of which is Lipitor, due to lose patent exclusively in 2011. An increase in the no. of safety issues surrounding Viagra.
37 6-Mar-13

Pfizer updates

The companys new marketing strategy, coupled with focused organisational, financial and R&D restructuring efforts, compensated for the losses caused by Lipitors patent expiry. The approval ofXalkori for lung cancer, Inlyta and pneumococcal vaccine Prevnar 13 have proved to be a real lifeline for Pfizer. Moving ahead, the steady progress of the late-stage pipeline(with 22 projects in phase III and 11 under registration) will be a primary source of confidence for the company.
38

6-Mar-13

Pfizer updates

The key strategy of the group is now to advance experimental drugs towards approval: these include Bosutinib, Tofacitinib, experimental clot-preventing drug Eliquis and its many pipeline drugs to make up for the inevitable decline in Lipitor revenue. With a view to reducing costs, Pfizers huge research budget has been cut by 12%. In 2012, Pfizer will focus on small to mid-sized deals and effective research partnerships to strengthen its portfolio in all therapeutic segments.
39 6-Mar-13

40

6-Mar-13